(Q33491961)

27 July 2017

Preclinical and phase I trials of topoisomerase I inhibitors (English)

1 reference

27 July 2017

phase I clinical trial

0 references

author name string

D D Von Hoff

1

1 reference

27 July 2017

H A Burris

2

1 reference

27 July 2017

J Eckardt

3

1 reference

27 July 2017

M Rothenberg

4

1 reference

27 July 2017

S M Fields

5

1 reference

27 July 2017

S F Chen

6

1 reference

27 July 2017

J G Kuhn

7

1 reference

27 July 2017

1 January 1994

1 reference

Cancer Chemotherapy and Pharmacology

27 July 2017

1 reference

27 July 2017

34 Suppl

1 reference

27 July 2017

S41-5

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00684862

27 July 2017

0 references

cites work

Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities

1 reference

12 December 2020

He's not going to talk about in vitro predictive assays again, is he?

1 reference

12 December 2020

Prospective clinical trial of a human tumor cloning system

1 reference

12 December 2020

Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series

1 reference

12 December 2020

Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents

1 reference

12 December 2020

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

12 December 2020

Application of a human tumor colony-forming assay to new drug screening

1 reference

12 December 2020

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

1 reference

12 December 2020

Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician

1 reference

12 December 2020

Primary Bioassay of Human Tumor Stem Cells

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.

1 reference

12 December 2020

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00684862

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference